Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsDavid Erbe, James D. McIninch
Life of this patent
Estimating the term…
Abstract
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the proline dehydrogenase 2 (PRODH2) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a PRODH2 gene and to methods of preventing and treating a PRODH2-associated disorder, e.g., primary hyperoxalurias and/or kidney stone diseases.
Claims32
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of proline dehydrogenase 2 (PRODH2) in a cell,
- a) wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequence of SEQ ID NO:1, and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequence of SEQ ID NO:
- 2;
- b) wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a region of complementarity to an mRNA encoding PRODH2, and wherein the region of complementarity comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences in any one of Tables 2-3;
- or
- c) wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequence of nucleotides 47-69, 262-284, 273-295, 545-567, 611-633, 655-677, 942-964, 949-971, 1119-1141, 1173-1195, 1183-1205, 1215-1237, 1243-1265, 1249-1271, 1254-1276, 1354-1376, 1436-1458, and 1444-1466 of SEQ ID NO:1, and the antisense strand comprises at least 15 contiguous nucleotides from the corresponding nucleotide sequence of SEQ ID NO:
- 2.
-6. (canceled)
(canceled)
(canceled)
-15. (canceled)
-20. (canceled)
(canceled)
-39. (canceled)
-46. (canceled)
-57. (canceled)
(canceled)
-75. (canceled)
-79. (canceled)
Dependencies are inferred from the claim text.